Abstract

The role played by cytokines, other than interferon (IFN)-α, in the differentiation and function of dendritic cells (DCs) in systemic lupus erythematosus (SLE), remains unclear. Serum interleukin-10 (IL-10) levels are generally elevated in SLE patients, which might modulate the differentiation of DCs. In this study, DCs were induced from monocytes either by transendothelial trafficking or by culture with granulocyte-macrophage colony-stimulating factor (GM-CSF) + IL-4 + tumor necrosis factor (TNF)-α. Both systems were used to investigate the effects of elevated serum IL-10 level on DC differentiation in SLE patients. The results showed that monocyte-derived DCs induced by either SLE serum or exogenous IL-10 reduced the expression of human leukocyte antigen (HLA)-DR and CD80, decreased IL-12p40 level, and increased IL-10 level, and exhibited an impaired capacity to stimulate allogenic T-cell proliferation. These results indicate that serum IL-10 may be involved in the pathogenesis of SLE by modulating the differentiation and function of DCs.

Keywords: lupus erythematosus systemic (SLE), interleukin-10 (IL-10), dendritic cells (DCs), differentiation

INTRODUCTION

Dendritic cells (DCs) are key regulators in immune responses capable of priming naive T cells and initiating primary T-cell responses when they are pulsed with antigenic peptides or proteins, and they are also capable of inducing anergy in autoreactive T cells. T-cell populations show functional disorders in systemic lupus erythematosus (SLE), such as abnormal activation of autoreactive T cells, and defects in responses
to microbial antigens. These disorders may result from underlying defects in the function of DCs. It is indicated that both DCs and cytokines are involved in the induction of autoimmune diseases\cite{1}. Phenotypic and functional abnormalities have been described in DCs isolated from patients with SLE\cite{2} and it is believed that abnormal DCs play an important role in the pathogenesis of SLE. It has been shown that interferon (IFN)-\(\alpha\) derived from the sera of SLE patients induces normal monocytes to differentiate into DCs, which could capture antigens from apoptotic cells and present them to CD4\(^+\) T cells\cite{3}. The central role of DCs and IFN-\(\alpha\) in SLE has received much attention\cite{4-6}. Recently, the IFN-induced protein, IFN-induced protein with tetratricopeptide repeats 4 (IFIT4), was found to be associated with SLE, and to promote the differentiation of monocytes into DC-like cells, supporting the key role of IFN-\(\alpha\) in the pathogenesis of SLE\cite{7}. However, there is a disorder of multiple cytokines in patients with SLE, in whom abnormal elevation of interleukin (IL)-1\(\beta\), IL-6, IL-10, IL-17 or IL-23 is detected\cite{8-10}. Our previous study demonstrated that IL-6 in SLE serum significantly affected the differentiation and function of DCs derived from CD34\(^+\) haematopoietic precursor cells (HPCs) and promoted the expression of human leukocyte antigen (HLA)-DR, CD80 and CD86, IL-10 production and the ability to stimulate allogenic T-cell proliferation, while decreasing IL-12 secretion by DCs\cite{11}. The role played by cytokines, other than IFN-\(\alpha\) and IL-6, in the differentiation and function of DCs in SLE patients remains unclear till now.

IL-10 has both immunosuppressive and immunostimulatory properties, and its potential for dampening inflammatory responses has attracted much interest in research of autoimmune diseases\cite{12}. Increased IL-10 production by SLE peripheral blood B cells and monocytes is observed, which is thought to correlate with disease activity\cite{13}. Inhibition of IL-10 activity by neutralizing antibodies results in decreased expression of disease markers in both SLE patients and murine models of lupus\cite{14,15}. The results of these studies are explained by the intrinsically high levels of IL-10 related to lupus susceptibility and severity through the promotion of B-cell proliferation, and immune stimulation by this cytokine seems to trump immunosuppression in lupus patients. However, the effect of serum IL-10 on the differentiation and function of DCs in pathogenesis of SLE remains unclear. IL-10 has been demonstrated to inhibit the differentiation and function of DCs by reducing the expression of co-stimulators and major histocompatibility complex (MHC)-II molecule and IL-12 production\cite{16-18}. It is, therefore, hypothesized that increased levels of IL-10 in the serum of SLE patients may modulate the differentiation of DCs. The major purpose of this study was to obtain the direct evidence of the effects of IL-10 present in the serum of SLE patients on the differentiation and function of monocyte-derived DCs (MDDCs).

**SUBJECTS AND METHODS**

**Subjects**

Totally 50 SLE patients recruited during routine clinic visits to the Department of Rheumatology, the First Affiliated Hospital of Nanjing Medical University, were enrolled in this study. All of the patients met the revised SLE criteria of the American Rheumatism Association\cite{19}. The patients were all female, with a median age of 29 years (range, 24-37 years). Thirteen age-matched healthy female volunteers served as controls. Informed consent was obtained from all subjects.

**Serum preparation**

The blood samples were collected from all participants and allowed to clot at room temperature for 2 h. The sera were separated by centrifugation at 2000 rpm for 10 min and stored in aliquots at -20°C until required. The IL-10 concentrations in the sera from SLE patients were measured using ELISA reagent kits (Diaclone Research; Besancon Cedex, France) according to the manufacturer’s instructions. The sera with different levels of IL-10 were selected, grouped and pooled, and the sera were grouped as follows: Group 1, SLE sera with normal levels of IL-10 (< 10 pg/mL); Group 2, SLE sera with mildly elevated levels of IL-10 (10-20 pg/mL); Group 3, SLE sera with highly elevated levels of IL-10 (20-40 pg/mL).

**Separation of peripheral blood mononuclear cells (PBMCs)**

Peripheral blood from healthy donors was supplied by Jiangsu Province Blood Centre. Heparinized blood (200 mL) was collected from each donor and PBMCs were isolated by standard ficoll-Hypaque density-gradient centrifugation for 2 h. PBMCs were then washed twice with phosphate buffered saline (PBS) before use.

**Induction of DCs**

DCs were induced from monocytes by two methods, transendothelial trafficking and culture with granulocyte-macrophage colony-stimulating factor (GM-CSF) + IL-4 + tumor necrosis factor \(\alpha\) (TNF-\(\alpha\)). Transendothelial trafficking was performed using a method modified from Randolph et al.\cite{20}. Fresh hu-
man umbilical cord was collected from Nanjing Maternity and Children Health Care Hospital. Within 4 h of delivery the umbilical vein was washed with PBS and the endothelial layer was digested with 0.25% trypsin (Invitrogen; Carlsbad, CA, USA). Human umbilical vein endothelial cells (HUVECs) were collected and identified by factor VIII-related antigen staining using fluorescence microscopy (Olympus; Tokyo, Japan). HUVECs were grown on polymerized collagen gels and cultured in RPMI 1640 (GIBCO; Carlsbad, CA, USA) supplemented with 20% fetal calf serum (FCS) (Hyclone; Waltham, MA, USA) for 2 d until full confluency. PBMCs from healthy donors were then incubated with the endothelial monolayer for 2 h before a thorough and careful wash to remove non-migrated cells. The phenotypes (CD14, CD11c, HLA-DR, CD80, and CD86) of both the freshly isolated PBMCs before incubation, and the non-migrated cells after incubation, were analyzed by flow cytometry to enumerate the migrated population. After a further culture for 36 h, the cells that had reverse-transmigrated across the endothelial monolayer were harvested and identified.

In the GM-CSF+IL-4+TNF-α culture system, monocytes were isolated from PBMCs by adhesion to plastic plates for 1 h followed by culture in RPMI 1640 containing 20% FCS in the presence of 1,000 U/mL TNF-α (PeproTech; Rocky Hill, NJ, USA) supplemented with 20% FCS for 48 h. The concentrations of IL-12p40, IFN-γ and IL-10 in the culture supernatants were measured using commercial ELISA reagent kits (Diaclone Research; Besancon Cedex, France) according to the manufacturer’s instructions.

Determination of cytokine levels produced by DCs

After washing twice with PBS, cells were seeded at a concentration of 1.5×10⁷/mL onto 24-well plates and incubated in RPMI 1640 supplemented with 20% FCS for 48 h. The concentrations of IL-12p40, IFN-γ and IL-10 in the culture supernatants were measured using commercial ELISA reagent kits (Diaclone Research; Besancon Cedex, France) according to the manufacturer’s instructions.

Measurement of allostimulatory capability of DCs

The allostimulatory capability of DCs was measured in an allogeneic mixed leukocyte reaction (MLR). CD3⁺ T cells purified from PBMCs by a magnetic cell sorting system using anti-human CD3 microbeads (Miltenyi Biotec; Bergisch Gladbach, Germany) were used as effector cells, and were seeded at a density of 2×10⁵ cells/well onto 96-well microtiter plates (Corning; Lowell, MA, USA). The harvested DCs were used as stimulator cells and seeded at DC:T cell ratios of 1:10, 1:20, 1:50 and 1:100. The cells were co-incubated in RPMI 1640 supplemented with 10% FCS for 96 h. T cell proliferation was then measured by tritiated thymidine ([³H] TdR) incorporation or by cell counting kit-8 (CCK-8, Dojindo Laboratories; Kumamoto, Japan). For measurement using the [³H] TdR incorporation method, 0.5 µCi/well [³H] TdR (Amersham; Braunschweig, Germany) was added for the last 16 h of co-culture. [³H] TdR incorporation was determined in preliminary dose-response experiments (3-15 ng/mL).

Morphological observation

DCs induced by the transendothelial trafficking method were collected and observed by light microscopy and scanning electron microscopy (SEM). Cells were washed twice with PBS, transferred onto slides and spun. After fixating in methanol, cells were stained with Wright-Giemsa solution and analyzed under a light microscope (Olympus; Tokyo, Japan; original magnification, ×100). DCs were fixed using 2.5% glutaraldehyde for SEM and post-fixed in 1% osmium tetroxide. Following dehydration through ethyl alcohol and propylene oxide, the cells were critical point-dried in CO₂ and sputter-coated with gold. Samples were then analyzed under a scanning electron microscope (JEOL; Tokyo, Japan; original magnification, ×8000).

Phenotypic analysis

Cells were washed, resuspended in PBS and then conjugated with anti-CD14-fluorescein isothiocyanate (FITC), anti-CD11c-FITC, anti-HLA-DR-phycocerythrin (PE), anti-CD80-PE, anti-CD86-PE, anti-CD83-PE, anti-CD1a-FITC monoclonal fluorescence antibodies or isotype controls (eBioscience; San Diego, CA, USA) at 4°C for 30 min. After washing twice with PBS, cells were analyzed using flow cytometry (BD Biosciences; San Jose, CA, USA). Data analysis was performed using the software CellQuest (BD Biosciences).

Measurement of cytokine levels produced by DCs

After washing twice with PBS, cells were seeded at a concentration of 1.5×10⁷/mL onto 24-well plates and incubated in RPMI 1640 supplemented with 20% FCS for 48 h. The concentrations of IL-12p40, IFN-γ and IL-10 in the culture supernatants were measured using commercial ELISA reagent kits (Diaclone Research; Besancon Cedex, France) according to the manufacturer’s instructions.
then measured using a β-scintillation counter (Perkin Elmer; Shelton, CT, USA). Results were expressed as the stimulation index (SI) calculated using the following formula. SI = (CPM<sub>experimental well</sub> - CPM<sub>blank well</sub>) / (CPM<sub>negative control well</sub> - CPM<sub>blank well</sub>), while CPM indicates cell counts per min. For detection using CCK-8, the cells were pulsed with 20 μL/well CCK-8 solution and incubated for 2 h. The optical density (OD) was then measured at 450 nm using a microplate reader (CliniBio; Eugendorf, Austria). Results were expressed as SI calculated using the following formula. SI = (OD<sub>experimental well</sub> - OD<sub>blank well</sub>) / (OD<sub>negative control well</sub> - OD<sub>blank well</sub>). Each experiment was done in triplicate.

Statistical analysis

All data were presented as mean ± standard deviation (SD), and all statistical analyses were performed using the statistical software SPSS version 11.5 (SPSS Inc; Chicago, IL, USA). Two-group paired comparisons were assessed using paired t-test, and one-way analysis of variance (ANOVA) was used to test the difference of means among groups. The Student-Newman-Keuls (SNK) method was used for pairwise comparisons of the means. A P-value < 0.05 was considered statistically significant.

RESULTS

SLE serum affects the differentiation and function of DCs induced by transendothelial trafficking

HUVECs were identified by factor VIII-related antigen staining. Intensive green fluorescence was observed in the cytoplasm of most HUVECs by fluorescence microscopy (supplementary Fig. 1A available online). After culture on polymerized collagen gels for 2 d, HUVECs formed confluent endothelial monolayers (supplementary Fig. 1B available online). PBMCs were incubated on these monolayers for 2 h and then the non-migrated cells were removed. As shown in Fig. 1A, the proportion of CD11c<sup>+</sup> and CD14<sup>+</sup> cells in the non-migrated cells significantly decreased after the incubation, while the number of CD3<sup>+</sup> cells increased compared with that seen in the PBMCs before the incubation. No significant changes in the proportion of HLA-DR<sup>+</sup>, CD80<sup>+</sup>, CD86<sup>+</sup> and CD19<sup>+</sup> cells were observed, indicating that monocytes (CD11c<sup>+</sup> CD14<sup>+</sup>), rather than T (CD3<sup>+</sup>) or B cells (CD19<sup>+</sup>), migrated through the endothelial monolayer.

After further culture for 36 h, the cells that reverse-transmigrated across the endothelial monolayer were harvested and identified. Under a light microscope and scanning electron microscope, these cells displayed typical morphology of DCs, with many dendritic-like protrusions on the cell surface (supplementary Fig. 2 available online). These cells expressed low level of CD14 and high level of HLA-DR, CD80, CD86 and CD11c (Fig. 1B), and showed a strong capacity to stimulate allogenic T cell proliferation (Fig. 2A). According to these characteristics, the reverse-transmigrated cells induced by the transendothelial trafficking model were considered as DCs.

In the transendothelial trafficking model, MDDCs induced by the SLE serum (in which IL-10 level was elevated while the levels of other cytokines were not measured), displayed a significantly increased capacity to stimulate allogenic T cell proliferation compared with those induced by the normal serum. Neutralization of IL-10 in the SLE serum led to further increases in the stimulatory capacity of the MDDCs. In contrast,
MDDCs induced by the normal serum supplemented with exogenous IL-10 showed a significantly decreased allostimulatory capability than those induced by the normal serum alone (Fig. 2B). These results suggest that, in SLE serum, some factors such as IFN-α and IL-6, rather than IL-10, enhance the capacity of MDDCs to stimulate allogeneic T cell proliferation, while IL-10 inhibits this capacity.

Therefore, the SLE serum containing highly elevated levels of IL-10 and normal levels of IFN-α and IL-6 was used in the following experiments. MDDCs induced by the SLE serum containing highly elevated levels of IL-10 and normal levels of IFN-α and IL-6, or MDDCs induced by the normal serum supplemented with exogenous IL-10, led to lower percentage of CD80-expressing cells compared with those induced by the normal serum alone. However, the percentages of HLA-DR and CD86-expressing cells were not changed (Fig. 3).

IL-10 in SLE serum decreases the expression of HLA-DR and CD80 by MDDCs induced by the GM-CSF + IL-4 + TNF-α culture system

Monocytes were isolated from PBMCs and cultured with GM-CSF + IL-4 + TNF-α. After 8 d of induction, these cells expressed high levels of HLA-DR, CD80 and CD86 (86.86% ± 6.92%, 86.62% ± 7.40% and 93.65% ± 4.34%, respectively, n = 5), and CD83 and CD1a (32.63% ± 9.49% and 43.11% ± 6.49%, respectively, n = 5). These cells also showed a strong capacity to stimulate allogeneic T cell proliferation (Fig. 4), indicating that monocytes had differentiated into DCs in this culture system.

In the GM-CSF + IL-4 + TNF-α culture system, MDDCs induced by SLE serum containing highly elevated levels of IL-10, expressed significantly reduced levels of HLA-DR and CD80 compared with those induced by the normal serum alone. The expression of CD80 on MDDCs induced by the SLE serum, containing mildly elevated levels of IL-10 also decreased (Fig. 5A). The inhibitory effects of SLE serum on the expression of HLA-DR and CD80 could be reversed by the addition of anti-IL-10 neutralizing antibodies into the SLE serum (Fig. 5B). Moreover, addition of exogenous IL-10 into the culture system resulted in decreased expression of HLA-DR, CD80 and CD86 by MDDCs compared with the normal controls (Fig. 5C).

IL-10 in SLE serum alters the cytokine production by MDDCs induced by the GM-CSF + IL-4 + TNF-α culture system

MDDCs induced by SLE serum containing highly elevated levels of IL-10 showed decreased production of IL-12p40, but increased IL-10 production, in comparison with those induced by the normal serum alone.
Serum IL-10 inhibits DC differentiation in SLE

Fig. 3 Effects of SLE serum on the phenotype of MDDCs induced by the transendothelial trafficking model. MDDCs are induced by the transendothelial trafficking model and the expression of HLA-DR, CD80 and CD86 is determined by flow cytometry. Normal serum group, MDDCs are induced by the normal serum; SLE serum group, MDDCs are induced by the SLE serum with highly elevated levels of IL-10 (20-40 pg/mL) and normal levels of IFN-α and IL-6; IL-10 neutralized group, MDDCs are induced by the SLE serum plus anti-IL-10 neutralizing antibodies; Isotype control group, MDDCs are induced by the SLE serum plus rabbit anti-human IgG isotype controls; Exogenous IL-10 group, MDDCs are induced by the normal serum supplemented with exogenous IL-10 (30 pg/mL). A: The results of flow cytometry of different groups. B: The statistical results of flow cytometry. Results are expressed as mean±SD of the percentage of positive cells. Data are obtained from six independent experiments. *P<0.05.

Fig. 4 Alloglutimulatory capacity of the cells induced by the GM-CSF + IL-4 + TNF-α culture system. The cells induced by GM-CSF + IL-4 + TNF-α, or monocytes isolated from PBMCs, are used as stimulator cells and incubated with allogeneic CD3+ T cells at ratios of 1:10, 1:20, 1:50 and 1:100. T-cell proliferation is measured using cell counting kit-8. The degree of proliferation is indicated as the stimulation index (SI). Results are expressed as mean±SD. Data are obtained from five independent experiments. * P < 0.05.
Fig. 5 Effects of IL-10 on the phenotype of MDDCs induced by the GM-CSF + IL-4 + TNF-α culture system. A: MDDCs were cultured with GM-CSF + IL-4 + TNF-α, normal serum alone or with SLE serum containing different levels of IL-10. SLE serum group 1, SLE serum with normal levels of IL-10 (<10 pg/mL); SLE serum group 2, SLE serum with mildly elevated levels of IL-10 (10–20 pg/mL); SLE serum group 3, SLE serum with highly elevated levels of IL-10 (20–40 pg/mL). B: MDDCs are induced by the GM-CSF + IL-4 + TNF-α culture system with SLE serum containing highly elevated levels of IL-10 (20–40 pg/mL) or SLE serum plus anti-human IL-10 neutralizing antibodies. SLE serum plus rabbit anti-human IgG is served as isotype controls. C: MDDCs are induced by GM-CSF + IL-4 + TNF-α with or without exogenous IL-10 (30 pg/mL). The expression of HLA-DR, CD80, and CD86 is determined by flow cytometry. Results are expressed as mean±SD of the percentage of positive cells. Data are obtained from six independent experiments. * P < 0.05.

Fig. 6 Effects of IL-10 on the cytokine production by MDDCs induced by the GM-CSF + IL-4 + TNF-α culture system. A: MDDCs are induced by GM-CSF + IL-4 + TNF-α, normal serum, SLE serum containing highly elevated levels IL-10 (20–40 pg/mL), SLE serum plus anti-human IL-10 neutralizing antibodies or SLE serum plus rabbit anti-human IgG isotype controls. B: MDDCs are induced by GM-CSF + IL-4 + TNF-α with or without exogenous IL-10 (30 pg/mL). The expression of HLA-DR, CD80, and CD86 is determined by flow cytometry. Results are expressed as mean±SD. Data are obtained from six independent experiments. * P < 0.05.
Neutralization of IL-10 in the SLE serum reversed these changes (Fig. 6A). Addition of exogenous IL-10 into the culture system decreased the production of IL-12p40 and increased the secretion of IL-10 by MDDCs as compared with the normal controls (Fig. 6B).

**IL-10 in SLE serum decreases the allostimulatory capacity of MDDCs induced by the GM-CSF + IL-4 + TNF-α culture system**

MDDCs induced by SLE serum containing highly elevated levels of IL-10 exhibited a reduced ability to stimulate allogenic T cell proliferation compared with those induced by normal serum alone at all DC:T cell ratios tested, and addition of anti-IL-10 neutralizing antibodies into the SLE serum reversed these changes at DC:T cell ratios of 1:10, 1:20 and 1:50 (Fig. 7A). Moreover, addition of exogenous IL-10 into the culture system decreased the allostimulatory capacity of MDDCs at DC:T cell ratios of 1:10 and 1:20 compared with the normal controls (Fig. 7B).

**DISCUSSION**

Although SLE has been recognized primarily as a B-cell-induced disease characterized by the production of pathogenic auto-antibodies, the contribution of T cells to the activation of autoreactive B cells is unquestionable. It is well known that the activation of autoreactive B cells is dependent upon the assistance offered by T cells, while the activation of autoreactive T cells is dependent upon stimulation by DCs. It has been demonstrated that IFN-α present in SLE serum induces monocytes to differentiate into DCs that are able to present self-antigens to T cells and activate autoreactive T cells, and both IFN-α and DCs have been considered to play central roles in the development of SLE. Furthermore, IFN-α has been considered as a target for SLE treatment. However, IFN-α is not the only cytokine found to be abnormally elevated in the serum of SLE patients. Increased levels of IL-10 are seen in the serum of SLE patients more frequently than IFN-α. It has been shown that serum IL-10 levels and the number of IL-10-producing PBMCs or T lymphocytes are increased in SLE patients, and that IL-10 production is positively correlated with the production of anti-double stranded DNA (dsDNA) antibodies. IL-10 has been shown to significantly affect the differentiation, maturation and function of DCs derived from monocytes. IL-10 inhibits the expression of HLA-DR, CD80, CD83 and CD86, and the production of IL-12 promotes the production of autocrine IL-10 and suppresses the allogenic T-cell stimulatory capacity of DCs. Whether IL-10 in the serum of SLE patients plays a similar role in the pathogenesis of SLE remains unknown. It was found that DCs from SLE patients expressed lower levels of HLA-DR, CD80 and CD89 than those from the normal controls. In addition, there is a different response to IL-10 treatment between DCs derived from the monocytes isolated from SLE patients and those from normal controls. However, the abnormal effects of serum environment, particularly the increased level of IL-10 on the development and function of DCs in SLE patients are not well known.

In this study, the phenotypic and functional analyses were performed to investigate the effects of IL-10 present in the serum of SLE patients on the differentiation of MDDCs induced by the GM-CSF + IL-4 + TNF-α culture system. A: MDDCs are induced by GM-CSF + IL-4 + TNF-α with normal serum, SLE serum containing highly elevated levels IL-10 (20-40 pg/mL), SLE serum plus anti-human IL-10 neutralizing antibodies or SLE serum plus rabbit anti-human IgG isotype controls. B: MDDCs are induced by GM-CSF + IL-4 + TNF-α with or without exogenous IL-10 (30 pg/mL). DCs are then used as stimulator cells and incubated with allogeneic CD3+ T cells at DC:T cell ratios of 1:10, 1:20, 1:50 and 1:100. T-cell proliferation is measured using cell counting kit-8. The degree of proliferation is indicated as the stimulation index (SI). Results are expressed as mean±SD. Data are obtained from six independent experiments. * P < 0.05.
ation of DCs derived from monocytes. There are various methods for inducing monocytes to differentiate into DCs. One common method involves culture of monocytes with GM-CSF and IL-4. In 1998, a new method was established to induce human monocytes to differentiate into DCs using a transendothelial trafficking model[20]. In this model, monocytes migrate across an endothelial monolayer into the sub-endothelial collagen. The cells then reverse-transmigrate back to the apical surface of the endothelial monolayer. During this process, monocytes differentiate into DCs. This process, to a certain degree, simulates the in vivo differentiation of DCs from monocytes[33]. Then, the DC-differentiating potential of mouse monocytes was demonstrated using this transendothelial trafficking model[34].

The present study established a transendothelial trafficking model, and used it to induce human monocytes to differentiate into DCs. The results showed that, after incubation with an endothelial monolayer for 2 h, the proportion of CD11c+ and CD14+ cells in the PBMC population was reduced, indicating that monocytes had migrated through the endothelial monolayer into the sub-endothelial collagen. After the non-migrating cells were removed, the cells obtained after reverse transmigration displayed typical morphological and phenotypic characteristics, and immunostimulatory activity of DCs. In this transendothelial trafficking model, neutralization of IL-10 in the SLE serum by anti-IL-10 antibody increased the allostimulatory capacity of MDDCs, and addition of exogenous IL-10 to the normal serum decreased the allostimulatory capability of MDDCs. These results suggest that IL-10 in SLE serum has inhibitory effects on the allostimulatory capacity of MDDCs. Moreover, if SLE serum containing highly elevated levels of IL-10 was added into the culture system, the induced MDDCs showed reduced expression of CD80. Normal serum supplemented with exogenous IL-10 had similar effects, indicating that IL-10 in SLE serum inhibited the phenotypic maturation of MDDCs.

In order to further examine the effects of IL-10 in SLE serum, DCs were induced from monocytes using the GM-CSF + IL-4 + TNF-α culture system. After 8 d of culture, the cells showed high levels of HLA-DR, CD80, CD86, CD83 and CD1a, and a strong capacity to stimulate allogenic T-cell proliferation, as well as typical characteristics of DCs. After culture with GM-CSF + IL-4 + TNF-α, the MDDCs induced by the SLE serum showed reduced expression of HLA-DR (P < 0.05), CD80 (P < 0.05) and CD86 (P > 0.05) in an IL-10 dose-dependent manner compared with those induced by the normal serum alone. After neutralization of IL-10 in SLE serum, the expression of HLA-DR and CD80 was restored. These results suggest that the high levels of IL-10 present in SLE serum inhibit the expression of CD80 and HLA-DR by MDDCs. This finding is supported by the experiments incorporating exogenous IL-10. Furthermore, MDDCs induced by the SLE serum produced lower levels of IL-12p40 and higher levels of IL-10, and displayed a decreased capacity to stimulate allogenic T-cell proliferation compared with those induced by the normal serum alone. Neutralization of the IL-10 in SLE serum increased IL-12p40 production, decreased the production of IL-10 and increased the allostimulatory capacity of MDDCs. These results suggest that IL-10 present in the serum of SLE patients significantly affects the differentiation and function of MDDCs.

The mechanism underlying the inhibitory effects of IL-10 on MDDCs has been partially elucidated. It was found that the immunoregulation of IL-10 governing the maturation and activation of DCs was mediated via suppression of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and of IkB kinase activity[35]. Recently, the mitogen-activated protein kinase (MAPK) signaling pathway was shown to play an important role in the maturation of DCs[36]. It has been known that IL-10 inhibits the surface co-stimulatory molecule expression and the stimulatory activity of human MD-DCs by inhibiting the MAPKs, extracellular signal-regulated kinase 2 (ERK2), stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (c-JNK) and p38 MAPK pathways.

Actually, besides IL-10, abnormalities are found in a number of cytokines from patients with SLE[37]. IL-10 may modulate the development and function of DCs, as well as other cytokines and, thus, exhibit more complex effects. For example, it was reported that IFN-α could alter the function of IL-10 from an anti-inflammatory one to a proinflammatory one[38]. In IFN-α-primed and IL-10-stimulated cells, priming by IFN-α resulted in greatly enhanced signal transducers and activators of transcription1 (STAT1) activation in response to IL-10, subsequently induced IFN-γ-inducible protein-10 (IP-10/CXCL10) and finally induced IFN-γ and monokine production. Further studies should be carried out to investigate the complex effects of IL-10 combined with other cytokines.

In conclusion, our findings show that high levels of IL-10 in the serum of SLE patients significantly alters the phenotype, cytokine profile and the allostimulatory capacity of MDDCs, resulting in decreased expression of HLA-DR and CD80, reduced production of IL-12p40, increased production of IL-10 and a decreased capacity to stimulate allogenic T-cell proliferation. Alterations of the biological characteristics of DCs...
may result in defective T cell response to microbial antigens in SLE.

References

[1] Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-80.

[2] Scheinecker C, Zwölfer B, Köller M, Münser G, Smeal JS. Alterations of dendritic cells in systemic lupus erythematosus: phenotypic and functional deficiencies. Arthritis Rheum 2001;44:856-65.

[3] Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001;294:1540-3.

[4] Hardin JA. Directing autoimmunity to nucleoprotein particles: the impact of dendritic cells and interferon alpha in lupus. J Exp Med 2003;97:691-2.

[5] Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006;5:554-62.

[6] Koutouzov S, Mathian A, Dalloul A. Type-I interferons and systemic lupus erythematosus. Autoimmun Rev 2006;5:554-62.

[7] Huang X, Shen N, Bao C, Gu Y, Wu L, Chen S. Interferon-induced protein IFIT4 is associated with systemic lupus erythematosus and promotes differentiation of monocytes into dendritic cell-like cells. Arthritis Res Ther 2000;10:R91.

[8] Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Kläreskog L, Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000;18:565-70.

[9] Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in autoimmunity. Clin Immunol 2008;127:385-93.

[10] Zhang Z, Kyttariss VC, Tsokos GC. The role of IL-23/IL-17 axis in lupus nephritis. J Immunol 2009;183:3160-9.

[11] Zhang R, Xing M, Ji X, Gu L, Yang X, Wang H, et al. Interferon-a and Interleukin-6 in SLE serum induce the differentiation and maturation of dendritic cells derived from CD34+ hematopoietic precursor cells. Cytokine 2010;50:195-203.

[12] Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M. The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 2004;15:61-76.

[13] Hagiwara E, Gourley MF, Lee S, Klinman DK. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10: Interferon-gamma secreting cells in the peripheral blood. Arthritis Rheum 1996;39:379-85.

[14] Llorente L, Richaud-Patin Y, Garcia-Padilla C, Clare L, Jaker-Ocampo J, Cardiel MH, et al. Clinical and biological effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000;43:1790-800.

[15] Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Meen S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994;179:305-10.

[16] Corinti S, Albanesi C, la Sala A, Pastore S, Girolomoni G. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 2001;166:4312-8.

[17] Chan A, Baird M, Mercer AA, Fleming SB. Maturation and function of human dendritic cells are inhibited by orf virus-encoded interleukin-10. J Gen Virol 2006;87:3177-81.

[18] Loos M, Remaut E, Rottiers P, De Creus A. Genetically engineered Lactococcus lactis lactis secreting murine IL-10 modulates the functions of bone marrow-derived dendritic cells in the presence of LPS. Scand J Immunol 2009;69:130-9.

[19] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.

[20] Randolph GJ, Beaufieu S, Lebecque S, Steinman RM, Muller WA. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 1998;282:480-3.

[21] Miyamoto T, Min W, Lillehoj HS. Lymphocyte proliferation response during Eimeria tenella infection assessed by a new, reliable, nonradioactive colorimetric assay. Avian Dis 2002;46:10-6.

[22] Zhou Y, Yuan J, Pan Y, Fei Y, Qiu X, Hu N, et al. T cell CD40LG gene expression and the production of IgG by autologous B cells in systemic lupus erythematosus. Clin Immunol 2009;132:362-70.

[23] Morimoto S, Nakano S, Watanabe T, Tamayama Y, Mitsuo A, Nakiri Y, et al. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production. Rheumatology 2007;46:1083-6.

[24] Blanco P, Palucka AK, Pascual V, Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 2008;19:41-52.

[25] Jara LJ, Benitez G, Medina G. Prolactin, dendritic cells and systemic lupus erythematosus. Autoimmun Rev 2008;7:251-5.

[26] Ronnblo M, Alm GV, Eloranta ML. Type I interferon and lupus. Curr Opin Rheumatol 2009;21:47-7.

[27] Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, et al. Neutralization of interferon alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60:1785-96.

[28] Capper ER, Maskill JK, Gordon C, Blakemore AI. Interleukin (IL)-10, IL-1R and IL-12 profiles in active and quiescent systemic lupus erythematosus: Could longi-
Tudinal studies reveal patient subgroups of differing pathology? *Clin Exp Immunol* 2004;138:348-56.

[29] Gómex D, Correa PA, Gómex LM, Cadena J, Molina JF, Anaya JM. Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor-α protective? *Semin Arthritis Rheum* 2004;33:404-13.

[30] Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM, et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. *J Clin Immunol* 2007;27:461-6.

[31] Woszczech G, Chen LY, Nagineni S, Shelhamer JH. IL-10 inhibits cysteinyl leukotriene-induced activation of human monocytes and monocytes-derived dendritic cells. *J Immunol* 2008;180:7597-603.

[32] Figueroa-Vega N, Galindo-Rodriguez G, Bajana S, Portales-Pérez D, Abud-Mendoza C, Sánchez-Torres C, et al. Phenotypic analysis of IL-10-treated, monocyte-derived dendritic cells in patients with systemic lupus erythematosus. *Scand J Immunol* 2006;64:668-76.

[33] Ferrero E, Bondanza A, Leone BE, Manici S, Poggi A, Zocchi MR. CD14+ CD34+ peripheral blood mononuclear cells migrate across endothelium and give rise to immunostimulatory dendritic cells. *J Immunol* 1998;160:2675-83.

[34] León B, Martínez del Hoyo G, Parrillas V, Vargas HH, Sánchez-Mateos P, Longo N, et al. Dendritic cell differentiation potential of mouse monocytes: monocytes represent immediate precursors of CD8- and CD8+ splenic dendritic cells. *Blood* 2004;103:2668-76.

[35] Bhattacharyya S, Sen P, Wallet M, Long B, Baldwin AS Jr, Tisch R. Immunoregulation of dendritic cell by IL-10 mediated through suppression of the PI3K/Akt pathway and of IkB kinase activity. *Blood* 2004;104:1100-9.

[36] Nakahara T, Moroi Y, Uchi H, Furue M. Differential role of MAPK signaling in human dendritic cell maturation and Th1/Th2 engagement. *J Dermatol Sci* 2006;42:1-11.

[37] Lourenço EV, La Cava A. Cytokines in systemic lupus erythematosus. *Curr Mol Med* 2009;9:242-54.

[38] Sharif MN, Tassiulas I, Hu Y, Mecklenbrauker I, Tarakhovsky A, Ivashkiv LB. IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. *J Immunol* 2004;172:6476-81.
Serum IL-10 from systemic lupus erythematosus patients suppresses the differentiation and function of monocyte-derived dendritic cells

Zhida Sun\textsuperscript{a}, Rong Zhang\textsuperscript{b}, Huijuan Wang\textsuperscript{c}, Pengtao Jiang\textsuperscript{c}, Jiangquan Zhang\textsuperscript{c}, Mingshun Zhang\textsuperscript{c}, Lei Gu\textsuperscript{a}, Xiaofan Yang\textsuperscript{c}, Miaojia Zhang\textsuperscript{d}, Xiaohui Ji\textsuperscript{c*}

\textsuperscript{a}Department of Oral Mucosal Diseases, the Affiliated Stomatological Hospital, Nanjing Medical University, Nanjing, Jiangsu 210029, China;\textsuperscript{b}Laboratory Center for Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu 210029, China;\textsuperscript{c}Department of Microbiology and Immunology, Nanjing Medical University, Nanjing, Jiangsu 210029, China;\textsuperscript{d}Department of Rheumatology, the First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu 210029, China.

Received 09 October 2011, Revised 21 December 2011, Accepted 29 August 2012, Epub 31 October 2012

Supplementary Figures

**Fig. 1** Morphological identification of human umbilical vein endothelial cells (HUVECs). Freshly isolated HUVECs were spun onto slides and incubated with a rabbit antibody to human factor VIII-related antigen and a goat anti-rabbit IgG-FITC secondary antibody. Morphological analysis (A) was performed under fluorescence microscopy (original magnification $\times 2000$). HUVECs were then grown on polymerized collagen gels and cultured in RPMI 1640 supplemented with 20% FCS. By d 2, a confluent endothelial monolayer (B) was observed under an inverted phase-contrast microscope (original magnification: $\times 100$).

**Fig. 2** Morphological analysis of the reverse-transmigrated cells induced in the transendothelial trafficking model. A: Cells were spun onto slides, stained with Wright-Giemsa solution and observed by light microscopy (original magnification: $\times 100$). B: Cells were fixed, dehydrated, dried, gilded, and analyzed by scanning electron microscopy (original magnification: $\times 8000$).